Drug Profile
Rocapuldencel-T - Argos Therapeutics
Alternative Names: AGS-003; CMN-001Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Argos Therapeutics Inc
- Developer Argos Therapeutics Inc; CoImmune; GU Research Network; National Cancer Institute (USA); Roswell Park Cancer Institute
- Class Cancer vaccines; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Renal cell carcinoma
- Discontinued Non-small cell lung cancer
Most Recent Events
- 02 Oct 2023 CoImmune terminates phase-II trial in Renal cell carcinoma (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (Intradermal) (NCT04203901)
- 28 Feb 2019 CoImmune acquires CMN 001 from Argos Therapeutics (CoImmune website - July 2023)
- 01 Jun 2018 Updated Interim efficacy analysis from a phase III ADAPT trial in Reneal cell carcinoma (Metastatic) presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO- 2018)